OBJECTIVE: To examine the effectiveness of a dynamic jaw opening device as part of a multimodal treatment strategy for trismus in patients with head and neck cancer. DESIGN: Retrospective cohort study. SETTING: Tertiary care cancer center. PARTICIPANTS: Patients with head and neck cancer and trismus (N=20). INTERVENTION: All patients underwent assessment by a board-certified physiatrist and were referred to physical therapy for delivery of the DTS and instructed to progress use of the DTS to 30 minutes 3 times a day. Additional modalities for the treatment of trismus including pain medications and botulinum toxin injections were prescribed as clinically indicated. MAIN OUTCOME MEASURES: Change in maximal interincisal distance (MID) as documented in the medical record. RESULTS: The use of the DTS as part of multimodal therapy including physical therapy, pain medications, and botulinum toxin injections as deemed clinically appropriate resulted in an overall improvement of the MID from 16.5mm to 23.5mm (P<.001). Patients who could comply with the treatment recommendations for DTS treatment did better than those who could not, with an improvement of the MID from 16 mm to 27 mm (P<.001) versus 17 mm to 22 mm (P=.88). CONCLUSIONS: The DTS is a safe and effective component of a multimodal strategy for improving trismus associated with head and neck cancer and its treatment. Further investigation is needed to determine the relative efficacy of the treatment modalities available for trismus including physical therapy and other jaw stretching devices.
OBJECTIVE: To examine the effectiveness of a dynamic jaw opening device as part of a multimodal treatment strategy for trismus in patients with head and neck cancer. DESIGN: Retrospective cohort study. SETTING: Tertiary care cancer center. PARTICIPANTS: Patients with head and neck cancer and trismus (N=20). INTERVENTION: All patients underwent assessment by a board-certified physiatrist and were referred to physical therapy for delivery of the DTS and instructed to progress use of the DTS to 30 minutes 3 times a day. Additional modalities for the treatment of trismus including pain medications and botulinum toxin injections were prescribed as clinically indicated. MAIN OUTCOME MEASURES: Change in maximal interincisal distance (MID) as documented in the medical record. RESULTS: The use of the DTS as part of multimodal therapy including physical therapy, pain medications, and botulinum toxin injections as deemed clinically appropriate resulted in an overall improvement of the MID from 16.5mm to 23.5mm (P<.001). Patients who could comply with the treatment recommendations for DTS treatment did better than those who could not, with an improvement of the MID from 16 mm to 27 mm (P<.001) versus 17 mm to 22 mm (P=.88). CONCLUSIONS: The DTS is a safe and effective component of a multimodal strategy for improving trismus associated with head and neck cancer and its treatment. Further investigation is needed to determine the relative efficacy of the treatment modalities available for trismus including physical therapy and other jaw stretching devices.
Authors: Michael K Ghiam; Kyle Mannion; Mary S Dietrich; Kristen L Stevens; Jill Gilbert; Barbara A Murphy Journal: Support Care Cancer Date: 2017-02-13 Impact factor: 3.603
Authors: Sara C Parke; David Michael Langelier; Jessica Tse Cheng; Cristina Kline-Quiroz; Michael Dean Stubblefield Journal: Curr Oncol Rep Date: 2022-02-19 Impact factor: 5.075
Authors: Jeffrey M Straub; Jacob New; Chase D Hamilton; Chris Lominska; Yelizaveta Shnayder; Sufi M Thomas Journal: J Cancer Res Clin Oncol Date: 2015-04-25 Impact factor: 4.553
Authors: Adepitan A Owosho; Luciana M Pedreira Ramalho; Haley I Rosenberg; SaeHee K Yom; Esther Drill; Elyn Riedel; C Jillian Tsai; Nancy Y Lee; Joseph M Huryn; Cherry L Estilo Journal: J Craniomaxillofac Surg Date: 2016-06-16 Impact factor: 2.078
Authors: Shailesh M Gondivkar; Amol R Gadbail; Sachin C Sarode; Rima S Gondivkar; Shankargouda Patil; Rahul N Gaikwad; Monal Yuwanati Journal: J Oral Biol Craniofac Res Date: 2020-07-03
Authors: Jolanda I Kamstra; Jan L N Roodenburg; Carien H G Beurskens; Harry Reintsema; Pieter U Dijkstra Journal: Support Care Cancer Date: 2012-10-04 Impact factor: 3.603